Multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach
Respiratory syncytial virus (RSV) is primarily associated with respiratory disorders globally. Despite the availability of information, there is still no competitive vaccine available for RSV. Therefore, the present study has been designed to develop a multiepitope-based subunit vaccine (MEV) using...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Multidisciplinary Digital Publishing Institute
2020
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/86848/ http://psasir.upm.edu.my/id/eprint/86848/1/Multiepitope%20based%20subunit%20vaccine.pdf |
| _version_ | 1848860302988279808 |
|---|---|
| author | ul Qamar, Muhammad Tahir Shokat, Zeeshan Muneer, Iqra Ashfaq, Usman Ali Javed, Hamna Anwar, Farooq Bari, Amna Zahid, Barira Saari, Nazamid |
| author_facet | ul Qamar, Muhammad Tahir Shokat, Zeeshan Muneer, Iqra Ashfaq, Usman Ali Javed, Hamna Anwar, Farooq Bari, Amna Zahid, Barira Saari, Nazamid |
| author_sort | ul Qamar, Muhammad Tahir |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Respiratory syncytial virus (RSV) is primarily associated with respiratory disorders globally. Despite the availability of information, there is still no competitive vaccine available for RSV. Therefore, the present study has been designed to develop a multiepitope-based subunit vaccine (MEV) using a reverse vaccinology approach to curb RSV infections. Briefly, two highly antigenic and conserved proteins of RSV (glycoprotein and fusion protein) were selected and potential epitopes of different categories (B-cell and T-cell) were identified from them. Eminently antigenic and overlapping epitopes, which demonstrated strong associations with their respective human leukocyte antigen (HLA) alleles and depicted collective ~70% coverage of the world’s populace, were shortlisted. Finally, 282 amino acids long MEV construct was established by connecting 13 major histocompatibility complex (MHC) class-I with two MHC class-II epitopes with appropriate adjuvant and linkers. Adjuvant and linkers were added to increase the immunogenic stimulation of the MEV. Developed MEV was stable, soluble, non-allergenic, non-toxic, flexible and highly antigenic. Furthermore, molecular docking and molecular dynamics (MD) simulations analyses were carried out. Results have shown a firm and robust binding affinity of MEV with human pathogenic toll-like receptor three (TLR3). The computationally mediated immune response of MEV demonstrated increased interferon-γ production, a significant abundance of immunoglobulin and activation of macrophages which are essential for immune-response against RSV. Moreover, MEV codons were optimized and in silico cloning was performed, to ensure its increased expression. These outcomes proposed that the MEV developed in this study will be a significant candidate against RSV to control and prevent RSV-related disorders if further investigated experimentally. |
| first_indexed | 2025-11-15T12:43:05Z |
| format | Article |
| id | upm-86848 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T12:43:05Z |
| publishDate | 2020 |
| publisher | Multidisciplinary Digital Publishing Institute |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-868482021-11-22T02:28:06Z http://psasir.upm.edu.my/id/eprint/86848/ Multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach ul Qamar, Muhammad Tahir Shokat, Zeeshan Muneer, Iqra Ashfaq, Usman Ali Javed, Hamna Anwar, Farooq Bari, Amna Zahid, Barira Saari, Nazamid Respiratory syncytial virus (RSV) is primarily associated with respiratory disorders globally. Despite the availability of information, there is still no competitive vaccine available for RSV. Therefore, the present study has been designed to develop a multiepitope-based subunit vaccine (MEV) using a reverse vaccinology approach to curb RSV infections. Briefly, two highly antigenic and conserved proteins of RSV (glycoprotein and fusion protein) were selected and potential epitopes of different categories (B-cell and T-cell) were identified from them. Eminently antigenic and overlapping epitopes, which demonstrated strong associations with their respective human leukocyte antigen (HLA) alleles and depicted collective ~70% coverage of the world’s populace, were shortlisted. Finally, 282 amino acids long MEV construct was established by connecting 13 major histocompatibility complex (MHC) class-I with two MHC class-II epitopes with appropriate adjuvant and linkers. Adjuvant and linkers were added to increase the immunogenic stimulation of the MEV. Developed MEV was stable, soluble, non-allergenic, non-toxic, flexible and highly antigenic. Furthermore, molecular docking and molecular dynamics (MD) simulations analyses were carried out. Results have shown a firm and robust binding affinity of MEV with human pathogenic toll-like receptor three (TLR3). The computationally mediated immune response of MEV demonstrated increased interferon-γ production, a significant abundance of immunoglobulin and activation of macrophages which are essential for immune-response against RSV. Moreover, MEV codons were optimized and in silico cloning was performed, to ensure its increased expression. These outcomes proposed that the MEV developed in this study will be a significant candidate against RSV to control and prevent RSV-related disorders if further investigated experimentally. Multidisciplinary Digital Publishing Institute 2020 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/86848/1/Multiepitope%20based%20subunit%20vaccine.pdf ul Qamar, Muhammad Tahir and Shokat, Zeeshan and Muneer, Iqra and Ashfaq, Usman Ali and Javed, Hamna and Anwar, Farooq and Bari, Amna and Zahid, Barira and Saari, Nazamid (2020) Multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach. Vaccines, 8 (2). pp. 1-27. ISSN 2076-393X https://www.mdpi.com/2076-393X/8/2/288 10.3390/vaccines8020288 |
| spellingShingle | ul Qamar, Muhammad Tahir Shokat, Zeeshan Muneer, Iqra Ashfaq, Usman Ali Javed, Hamna Anwar, Farooq Bari, Amna Zahid, Barira Saari, Nazamid Multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach |
| title | Multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach |
| title_full | Multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach |
| title_fullStr | Multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach |
| title_full_unstemmed | Multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach |
| title_short | Multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach |
| title_sort | multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach |
| url | http://psasir.upm.edu.my/id/eprint/86848/ http://psasir.upm.edu.my/id/eprint/86848/ http://psasir.upm.edu.my/id/eprint/86848/ http://psasir.upm.edu.my/id/eprint/86848/1/Multiepitope%20based%20subunit%20vaccine.pdf |